

Results of Annual Meeting

MINNEAPOLIS, United States and BRISBANE, Australia 4 December 2025: Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announces that on Wednesday, December 3, 2025 at 5.00 p.m. US Central time (being 9.00 a.m. AEST on Thursday, December 4, 2025), the Company held an Annual Meeting of Stockholders (“Annual Meeting”) at which a quorum was present. The matters listed below were submitted to a vote of the Company’s stockholders at the Annual Meeting through the solicitation of proxies. Detailed descriptions of the proposals are included in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on November 10, 2025 (the “Proxy Statement”).

A total of 20,980,141 shares of the Company’s common stock were present at the Annual Meeting in person, by virtual attendance, or by proxy, which represents approximately 54.6% of the shares of common stock outstanding as of October 30, 2025, which is the record date for the Annual Meeting.

Proposal 1A: Election of John Seaberg as Director

The Company’s stockholders approved the election of John Seaberg as a Class I director to serve until the 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until the earlier of his death, resignation, disqualification or removal.

Votes For	Votes Against	Abstentions
14,305,918	2,366,543	580,841

Proposal 1B: Election of Gregory Moss as Director

The Company’s stockholders approved the election of Gregory Moss as a Class I director to serve until the 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until the earlier of his death, resignation, disqualification or removal.

Votes For	Votes Against	Abstentions
15,653,027	1,004,903	595,372

Proposal 2: Appointment of KPMG

The Company’s stockholders approved the ratification of the appointment of KPMG as the Company’s independent registered public accounting firm for the 2025 fiscal year.

Votes For	Votes Against	Abstentions
20,620,868	146,666	212,607



For personal use only

Proposal 3: Grant of RSUs to Wayne Paterson (IPO)

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 1,000,000 restricted stock units ("RSUs") to Wayne Paterson in connection with the Company's U.S. initial public offering (the "IPO"), on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,208,624	1,658,798	2,385,880

Proposal 4: Grant of RSUs to John Seaberg (IPO)

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 83,333 RSUs to John Seaberg in connection with the IPO, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,232,053	2,002,822	2,018,427

Proposal 5: Grant of RSUs to Stephen Denaro (IPO)

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 41,666 RSUs to Stephen Denaro in connection with the IPO, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,235,783	1,999,302	2,018,217

Proposal 6: Grant of RSUs to Gregory Moss

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 52,742 RSUs to Gregory Moss in connection with his appointment to the Board, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,526,644	1,707,591	2,019,067

Proposal 7: Grant of RSUs to David Roberts

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 52,742 RSUs to David Roberts in connection with his appointment to the Board, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,531,294	1,702,941	2,019,067

For personal use only

Proposal 8: Grant of RSUs to John Seaberg

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of \$250,000 (in grant date value) of RSUs to John Seaberg in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,102,222	2,166,611	1,984,469

Proposal 9: Grant of RSUs to Stephen Denaro

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of \$125,000 (in grant date value) of RSUs to Stephen Denaro in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,090,812	2,173,577	1,988,913

Proposal 10: Grant of RSUs to Gregory Moss

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of \$61,644 (in grant date value) of RSUs to Gregory Moss in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,150,782	2,112,607	1,989,913

Proposal 11: Grant of RSUs to David Roberts

The Company's stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of \$61,644 (in grant date value) of RSUs to David Roberts in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,143,511	2,119,468	1,990,323

Proposal 12: Adjustments for Employee Incentive Plan Exercise Price

The Company's stockholders approved, for the purposes of ASX Listing Rule 6.23.4 and for all other purposes, adjustments to the exercise price of certain stock options previously granted under the Company's Employee Incentive Plan, on the terms and conditions set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,230,229	2,029,493	1,993,580



For personal use only

Proposal 13: Amendments to 2017 and 2020 Incentive Plans

The Company's stockholders approved, for the purposes of ASX Listing Rule 6.23.4 and for all other purposes, amendments to the terms of stock options previously granted under the Company's 2017 Incentive Plan and 2020 Incentive Plan, as set out in the Proxy Statement.

Votes For	Votes Against	Abstentions
13,177,832	2,076,481	1,998,989

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR[®] Transcatheter Heart Valve (**THV**), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR[®] THV is made using a single piece of molded ADAPT[®] tissue, Anteris' patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by Stephen Denaro, Director.

For more information:

Investor Relations

investors@anteristech.com
 Debbie Ormsby
 Anteris Technologies Global Corp.
 +61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

mchatterjee@bplifescience.com
 Malini Chatterjee, Ph.D.
 Blueprint Life Science Group
 +1 917 330 4269

Website www.anteristech.com
 X @AnterisTech
 LinkedIn https://www.linkedin.com/company/anteristech

